About the Company
We do not have any company description for Molecular Templates, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MTEM News
Molecular Templates, Inc. (MTEM)
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage ...
Molecular Templates (NASDAQ: MTEM)
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary ...
What's Going On With Molecular Templates Stock?
Molecular Templates, Inc (NASDAQ:MTEM) shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. The Details ...
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
Molecular Templates (NASDAQ:MTEM) just reported results for the fourth quarter of 2023. Molecular Templates reported earnings per share of -73 cents. This was above the analyst estimate for EPS of ...
Molecular Templates to Cut 30% of Staff, Chief Medical Officer
Molecular Templates said it would lay off about 30% of its workforce and cut its chief medical officer as it looks to stretch its resources. The Austin, Texas-based biopharmaceutical company said ...
Molecular Templates reports progress in cancer therapy trial
AUSTIN, Texas - Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company, has presented interim data at the American Association for Cancer Research Annual Meeting in San ...
MTEM Molecular Templates, Inc.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in ...
What's Going On With Molecular Templates Stock?
Molecular Templates shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study. The company said MT-6402 was well-tolerated with no drug-related Grade 4 or ...
Molecular Templates Inc MTEM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Molecular Templates, Inc. (MTEM)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...